| abstract |
Disclosed is the use of low dose IFN-gamma in the treatment of interferon-sensitive diseases. IFN-gamma can be administered orally (preferably buccal or sublingual) or extragranular to enhance monocytes, neutrophils or B cell function, reduce acute inflammation, or treat cancer, bacteria or fungal diseases. . Also disclosed are pharmaceutical compositions containing low doses of IFN-gamma, together with pharmaceutically acceptable carriers suitable for oral administration. |